PMID- 27562641
OWN - NLM
STAT- MEDLINE
DCOM- 20171222
LR  - 20190116
IS  - 1029-2403 (Electronic)
IS  - 1026-8022 (Linking)
VI  - 57
IP  - 12
DP  - 2016 Dec
TI  - Rationale and motivating factors for treatment-free remission in chronic myeloid 
      leukemia.
PG  - 2739-2751
AB  - With BCR-ABL1 tyrosine kinase inhibitors (TKIs), such as imatinib, nilotinib, 
      dasatinib, bosutinib, and ponatinib, many patients with chronic myeloid leukemia 
      in chronic phase (CML-CP) can expect to live near-normal life spans. Current 
      treatment recommendations of the National Comprehensive Cancer Network and the 
      European LeukemiaNet state that patients with CML-CP should remain on TKI therapy 
      indefinitely. However, there is increasing evidence from clinical trials that 
      some patients with sustained deep molecular responses may be able to achieve 
      treatment-free remission (TFR), whereby they can suspend TKI therapy without 
      losing previously achieved responses. With many patients achieving deep molecular 
      responses to TKI therapy, there is growing interest in whether such patients can 
      achieve TFR. In addition, adverse events (AEs) with long-term TKI therapy, 
      including both the potential for later-emerging AEs and chronic, low-grade AEs, 
      represent a major motivator for oncologists and their patients to investigate the 
      feasibility of TFR. In this review, we provide an overview of data from TFR 
      clinical trials, discuss the importance of achieving a deep molecular response to 
      TKI treatment, and consider potential reasons for investigating TFR following TKI 
      therapy.
FAU - Caldemeyer, Lauren
AU  - Caldemeyer L
AD  - a Indiana Blood and Marrow Transplantation, Franciscan St. Francis Hospital and 
      Health Centers , Indianapolis , IN , USA.
FAU - Akard, Luke P
AU  - Akard LP
AD  - a Indiana Blood and Marrow Transplantation, Franciscan St. Francis Hospital and 
      Health Centers , Indianapolis , IN , USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20160810
PL  - United States
TA  - Leuk Lymphoma
JT  - Leukemia & lymphoma
JID - 9007422
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Protein Kinase Inhibitors)
RN  - EC 2.7.10.2 (Fusion Proteins, bcr-abl)
SB  - IM
MH  - Antineoplastic Agents/administration & dosage/*therapeutic use
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse effects/therapeutic use
MH  - Clinical Trials as Topic
MH  - Early Detection of Cancer
MH  - Fusion Proteins, bcr-abl/antagonists & inhibitors/genetics
MH  - Gene Expression
MH  - Humans
MH  - Leukemia, Myelogenous, Chronic, BCR-ABL Positive/diagnosis/*drug 
      therapy/genetics/*mortality
MH  - Mutation
MH  - Prognosis
MH  - Protein Kinase Inhibitors/administration & dosage/*therapeutic use
MH  - Recurrence
MH  - Remission Induction
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Chronic myeloid leukemia
OT  - deep molecular response
OT  - treatment-free remission
OT  - tyrosine kinase inhibitors
EDAT- 2016/08/27 06:00
MHDA- 2017/12/23 06:00
CRDT- 2016/08/27 06:00
PHST- 2016/08/27 06:00 [pubmed]
PHST- 2017/12/23 06:00 [medline]
PHST- 2016/08/27 06:00 [entrez]
AID - 10.1080/10428194.2016.1198959 [doi]
PST - ppublish
SO  - Leuk Lymphoma. 2016 Dec;57(12):2739-2751. doi: 10.1080/10428194.2016.1198959. 
      Epub 2016 Aug 10.